Search

everythinglearnresearchcommunity

for

Search:↓

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

The treatment is safe and shows promise for metastatic breast cancer.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Erlotinib can cause nonscarring hair loss and itchy skin.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

DFMO may help control hair growth and treat cancer.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

Increased ornithine decarboxylase makes normally tumor-resistant mice more sensitive to tumors.

Targeted cancer therapies often cause serious skin problems that need careful management.

M1 homeopathic complex may help slow melanoma cell growth.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

miR-22 helps skin cancer grow and spread by activating specific cell signals.

K6/ODC transgenic mice are effective for quickly identifying cancer-causing chemicals.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

Blocking the Hedgehog pathway may help overcome drug resistance in multiple myeloma.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Inhibiting ODC can prevent UV-induced skin cancer.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.